Early Phase Testing of Regenerative Therapies in Glaucoma

Jeffrey Goldberg, MD, PhD
University of California, San Diego (San Diego, California)
Year Awarded:
2015
Grant Duration:
April 1, 2014 to March 31, 2015
Disease:
Glaucoma
Award Amount:
$200,000
Grant Reference ID:
C2015200
Award Type:
Other
Award Region:
US Southwestern

This project was generously funded by an anonymous donor.

Jeffrey Goldberg, MD, PhD

Early Phase Testing of Regenerative Therapies in Glaucoma

Summary

To date, all approved anti-glaucoma medications address the pressure in the eye. While these medications are often effective, no medication thus-far addresses the damage glaucoma imparts on the optic nerve. This small phase I clinical trial is testing whether a small growth factor, called CNTF, can protect the optic nerve from damage by glaucoma, and to assess the feasibility of moving on to larger clinical trials. The CNTF is being delivered by a tiny device, called NT-501 encapsulated cell therapy (NT-501 ECT), that contain cells which deliver a steady stream of the growth factor to the retina. 

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.